In patients with Philadelphia (Ph) chromosome-positive leukemia, there is evidence for an inverse correlation between the size of the BCR portion retained in the Bcr-Abl protein and the aggressiveness of the leukemia. Breakpoints in the minor breakpoint cluster region (m-bcr) result in an e1a2 transcript and p190 BCR-ABL protein, which is associated with acute lymphoblastic leukemia (ALL), while breakpoints in the major bcr (M-bcr) generate e13a2 or e14a2 transcripts and p210 BCR-ABL , typical of chronic myeloid leukemia (CML). Last, breakpoints in the micro-bcr (m-bcr) lead to an e19a2 mRNA and p230 BCR-ABL protein, which is associated with the relatively benign chronic neutrophilic leukemia. 1 Thus, it appears that Bcr domains encoded by sequences 3 0 of exon e1 may attenuate the disease phenotype, a notion that can be tested by analyzing patients with atypical BCR-ABL fusions that lack or retain defined parts of BCR compared to p210 BCR-ABL and p190 BCR-ABL , respectively. Here, we describe three new patients with an unusual e8a2 BCR-ABL transcript and review their characteristics in the context of five previously published cases, for which we provide additional information.
The previously unreported cases (patients #1, 2 and 3) were diagnosed with CML based on typical peripheral blood findings and cytogenetics (Table 1) . In all cases, standard karyotyping indicated t(9;22)(q34;q11), but further molecular analysis by FISH and/or RT-PCR revealed an atypical e8a2 BCR-ABL fusion. In case #1, FISH for BCR-ABL using the LSI-bcr/abl ES probe (Vysis, Downer's Grove, IL, USA) was consistent with a breakpoint 5 0 of the M-bcr ( Figure 1a ). Multiplex RT-PCR for BCR-ABL showed an unusually large band (Figure 1b) . Sequencing of the PCR product identified a fusion between BCR exon e8 and ABL exon a2, with a 55 base pair (bp) insert, which perfectly matched an inverted sequence from ABL intron Ib. Standard immunoblotting of protein lysates from bone marrow mononuclear cells with anti-Abl antibody identified a 200 kDa protein (Figure 1c) . Similarly, in cases #2 and #3, atypically large bands were apparent by 'long' and multiplex PCR, respectively. Sequencing of PCR products after amplification with specifically designed primers revealed e8a2 BCR-ABL fusions, with inserts corresponding to intronic sequences from ABL intron Ia (case #2) or Ib (case #3) ( Table 1 ).
An extensive search revealed five additional patients with e8a2 BCR-ABL fusions (Table 1) . At diagnosis, most of these patients had thrombocytosis (median platelet count 569 Â 10 9 /l, range 216-1123), while white blood cell (WBC) counts were variable (median 42 Â 10 9 /l, range 4.7-146 Â 10 9 /l). One patient (#4), with a WBC count of only 4.7 Â 10 9 /l showed prominent dysplasia in the bone marrow and had only 20% Phpositive metaphases. No unique features were apparent in the eight patients with e8a2 BCR-ABL fusions. At a median followup of 36 months (range 4-97), two patients had died from blast crisis, one had died from an unrelated cause and five were alive, one after allogeneic BMT. Remarkably, none of the patients treated with interferon-a achieved even a minor cytogenetic remission (defined as o65% Philadelphia-positive metaphases), similar to patients with p190-positive CML. 1 The direct junction between BCR exon e8 and ABL exon a2 would generate a stop codon (UAG) at position 7 after the fusion. In one patient (#8), the open reading frame (ORF) was maintained as a consequence of a break in BCR exon e8, without interposition of additional genetic material. In all other patients, the ORF was preserved by insertion of intronic sequences of 15-151 bp between BCR and ABL, and in 3/7 cases this was additionally associated with a break in BCR exon e8. In five cases, the intronic sequences were from ABL intron Ib, in one case from intron Ia and in one case from the KIAA0376 gene that maps approximately 1 Mb telomeric to BCR on chromosome 22q. Interestingly, three patients showed interposition of an identical 55 bp inverted fragment from ABL intron Ib (nt 29 861-29 915, Genbank U07561), adjacent to which the ABL sequence exhibits a cryptic splice donor site. Although the precise structure of the breakpoints at the DNA level has only been determined in one case (#6), it is obvious that most e8a2 fusions must result from complex translocations that involve additional breakpoints within ABL or on chromosome 22. It has been suggested that the presence of Alu and translisin recognition sites flanking the translocation sites may increase the probability of such events. 2 Given the need for complex rearrangements, it is surprising that more patients with e8a2 BCR-ABL fusions have been reported than with any of the other atypical BCR-ABL mRNAs, including e6a2, which is in frame. 3 However, since atypical BCR-ABL fusions are found in less than 1% of CML patients, the differences may be a chance finding due to small numbers or reflect a reporting bias.
Compared to the typical p210 BCR-ABL , the protein derived from an e8a2 fusion (p200 BCR-ABL ) lacks the pleckstrin homology (PH) domain but, unlike p190 BCR-ABL , retains the DBL-like and CDC24 homology domains (Figure 1d ). PH domains are present in multiple proteins and bind phosphoinositides with varying degrees of affinity. 4 Although the PH domains in the context of DBL-family members bind phosphoinositide lipids only with low affinity, this interaction is crucial for the guanidine exchange function (GEF) of DBL-family proteins. 5 Bcr exhibits GEF activity towards RhoA, CDC42 and Rac, 6 small G proteins with multiple functions, including regulation of cell growth and cytoskeleton. Fibroblasts expressing p190 BCR-ABL , which lacks the DBL-like, CDC24 and PH domains, exhibit a more profound disruption of the actin cytoskeleton than cells expressing p210 BCR-ABL , and this has been linked to the more aggressive phenotype of p190 BCR-ABLpositive leukemia. 6 However, since p190 BCR-ABL exhibits increased tyrosine kinase activity, 7 it is not possible to ascribe the more aggressive behavior of p190 BCR-ABL -positive leukemia solely to the loss of the GEF function. In addition, it has been shown that replacement of the DBL-like domain (and part of the pH domain) with irrelevant sequences abrogates the transformation potential of p210 BCR-ABL , consistent with a positive rather than a negative impact on its transforming potential. 8 The series of patients compiled here is still too small to determine whether e8a2-positive CML is different from 'standard' CML. However, none of the patients who were treated with interferon-a achieved even a minor cytogenetic remission, similar to the rare CML patients with p190 BCR-ABL . 1 To conclusively address the question of a more aggressive phenotype, it will be necessary to study a larger number of patients with e8a2 BCR-ABL fusions or to assess the transforming potential of this variant in a murine leukemia model. BMT, bone marrow transplant; CCR, complete cytogenetic response; CHR, complete hematological response; F, female; Hb, hemoglobin; Hu, hydroxyurea; a-IFN, interferon-alpha; ins, insert; M, male; NA, not available.
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